Until Labs Secures $58 Million in Series A Funding for Innovation
Until Labs Secures $58 Million in Series A Funding
Until Labs has announced a significant advancement in medical technology by securing a $58 million Series A funding round. This funding, led by Founders Fund with contributions from Lux Capital and Field Ventures, is aimed at enhancing their innovative solutions for organ transplantation.
What is Until Labs Working On?
Until Labs is focused on revolutionizing the field of organ transplantation through the development of its cutting-edge organ cryopreservation products. Their technology enables the preservation of donor organs at temperatures suitable for indefinite storage, which can potentially allow for longer transport times and better match potential recipients.
Background on Cryopreservation Technology
Cryopreservation involves cooling biological materials to keep them in a state where they do not deteriorate over time. This process is crucial for organ transplants where timing is critical. Because of the current limitations of organ preservation, many organs are discarded due to timing issues. Until Labs aims to change that.
Team Growth and Development
The funding will also facilitate further growth among Until’s diverse team of experts in various disciplines such as chemistry, biology, mechanical engineering, electrical engineering, neuroscience, and surgery. This multidisciplinary approach is essential for the successful development of their technology.
The Key Benefits of Their Innovation
By extending the viability of donor organs, Until Labs' technology could help in reducing the number of discarded organs during the transplant process. Laura Deming and Hunter Davis, co-founders of Until Labs, emphasized the importance of their technology, stating that it aims to align the timing of organ delivery with the needs of patients and surgeons.
Future of Organ Transplantation
The overarching mission of Until Labs is ambitious — to build medical infrastructure that allows us to pause biological time at the organ level and ultimately lead towards comprehensive medical hibernation technology for whole-body preservation. This innovative approach could redefine how we view organ transplants.
Contact Information
Reach out to Until Labs for more information at hi@untillabs.com.
Frequently Asked Questions
What type of funding did Until Labs just receive?
Until Labs secured $58 million in a Series A funding round to develop organ cryopreservation technology.
Who led the funding round?
The funding round was led by Founders Fund with participation from Lux Capital and Field Ventures.
What is the main focus of Until Labs?
Until Labs focuses on developing technology that enhances organ preservation for transplant patients, aiming to improve the process and outcomes of organ transplants.
How does cryopreservation impact organ transplants?
Cryopreservation significantly extends the storage time of donor organs, allowing for better matching and utilization of available organs for transplant.
How can I contact Until Labs for more information?
You can reach Until Labs at hi@untillabs.com for inquiries or further information about their technology.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.